Department of Biochemistry, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Center for Complex Networks Science, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
J Cell Mol Med. 2021 Sep;25(18):8715-8724. doi: 10.1111/jcmm.16827. Epub 2021 Jul 30.
Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the motor symptoms. However, it does not affect the progression of the disease and its long-term use triggers severe complications. There are no bona fide biomarkers for monitoring the patients' response to LevoDopa and predicting the efficacy of levodopa treatment. Here, we have combined qPCR microRNA array screening with analysis of validated miRs in naïve versus Levodopa-treated PD patients. We have identified plasma miR-19b as a possible biomarker for LevoDopa therapy and validated this result in human differentiated dopaminergic neurons exposed to LevoDopa. In silico analysis suggests that the LevoDopa-induced miR-19b regulates ubiquitin-mediated proteolysis.
帕金森病（PD）是老年人中第二常见的神经退行性疾病，其诊断和预后主要基于临床症状。左旋多巴替代疗法是 PD 的金标准治疗方法，因为它可以改善运动症状。然而，它不能影响疾病的进展，而且长期使用会引发严重的并发症。目前还没有可靠的生物标志物来监测患者对左旋多巴的反应，也无法预测左旋多巴治疗的效果。在这里，我们将 qPCR 微 RNA 阵列筛选与未经治疗的 PD 患者与接受左旋多巴治疗的 PD 患者的验证微 RNA 分析相结合。我们发现血浆 miR-19b 可能是左旋多巴治疗的生物标志物，并在暴露于左旋多巴的人类分化多巴胺能神经元中验证了这一结果。计算机分析表明，左旋多巴诱导的 miR-19b 调节泛素介导的蛋白水解。
